

**Remarks**

In view of the above amendments based on our telephonic conversation Applicants request withdrawal of the rejections in the Office Action dated June 7, 2007.

Claims 1, 6, 7, 9-13, 16-27, 45-46 and 49-51 are pending with claims 1, 27 and 45 being independent.


Claims 1, 27 and 45 have been amended to include the limitation of screening the powder blend through a mesh after blending but before filling in capsules. Support for such amendment could be found at several places in the specification. For example, the process described in Examples 1-5, requires the blend prepared by mixing the active ingredient – phenytoin sodium – with the inactive ingredients to be screened through a No. 30 mesh before being filled in “0” hard gelatin capsules.

The Applicants would like point out that in doing the amendments, no matter has been added.

**Conclusion**

As the claims have been amended per the telephonic discussion, the Examiner is urged to pass claims 1, 6, 7, 9-13, 16-27, 45-46 and 49-51 to issue. Authorization is hereby given to charge any fees or credits due in connection with this Response to Office Action to Deposit Account No. 50-0912.

Respectfully submitted,

  
George E. Heibel, PhD, Reg. No. 42, 648

Date: October 30, 2007

Ranbaxy Inc.  
600 College Road East, Suite 2100  
Princeton, New Jersey 08540  
Tel: (609) 720-5334  
Fax: (609) 514-9779